Evidence of measureable disease on radiographic studies is not required for entry onto this protocol. Neurologic deficits in patients with CNS tumors should be relatively stable for a minimum of 2 weeks prior to study entry. Patients who are unable to walk because of paralysis, but who are in a wheelchair will be considered ambulatory for the purpose of assessing the performance score. Completed within one week prior to protocol entry. Patients who received substantial BM irradiation are excluded.
Patients post stem cell transplant are excluded.
All patients or their legal guardians must sign a document of informed consent which has been approved by the local Instituional Review Board. When appropriate the patient will included in all discussions in order to obtain verbal assent. The Phase I Office must give permission to register the patient. Registration must occur on the day the patient receives the treatment. However, the registration should precede the drug administration.